Outcome of Non-hematological Autoimmunity After Hematopoietic Cell Transplantation in Children with Primary Immunodeficiency.
Adolescent
Autoimmune Diseases
/ diagnosis
Autoimmunity
Child
Child, Preschool
Disease Management
Disease Susceptibility
Female
Graft vs Host Disease
/ diagnosis
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Immune Reconstitution
Incidence
Infant
Lymphocyte Count
Male
Primary Immunodeficiency Diseases
/ complications
Prognosis
Retrospective Studies
Risk Factors
Transplantation Chimera
Treatment Outcome
Primary immunodeficiency
children
post-transplant autoimmunity
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
23
08
2020
accepted:
12
10
2020
pubmed:
4
11
2020
medline:
15
1
2022
entrez:
3
11
2020
Statut:
ppublish
Résumé
Knowledge of post-hematopoietic cell transplantation (HCT) non-hematological autoimmune disease (AD) is far from satisfactory. This multicenter retrospective study focuses on incidence, risk factors, and outcomes of post-HCT AD in 596 children with primary immunodeficiency (PID) who were transplanted from 2009 to 2018. The indications of HCT were severe combined immunodeficiency (SCID, n = 158, 27%) and non-SCID PID (n = 438, 73%). The median age at HCT was 2.3 years (range, 0.04 to 18.3 years). The 5-year overall survival for the entire cohort was 79% (95% cumulative incidence (CIN), 74-83%). The median follow-up of surviving patients was 4.3 years (0.08 to 14.7 years). The CIN of post-HCT AD was 3% (2-5%) at 1 year post-HCT, 7% (5-11%) at 5 years post-HCT, and 11% (7-17%) at 8 years post-HCT. The median onset of post-HCT AD was 2.2 years (0.12 to 9.6 years). Autoimmune thyroid disorder (n = 19, 62%) was the most common post-HCT AD, followed by neuromuscular disorders (n = 7, 22%) and rheumatological manifestations (n = 5, 16%). All patients but one required treatment for post-HCT AD. After multivariate analysis, age at transplant (p = 0.01) and T cell-depleted graft (p < 0.001) were significant predictors of post-HCT AD. None of the T cell-depleted graft recipients developed post-HCT AD. Patients with a lower CD3+ count at 6 months post-HCT had a significant higher incidence of post-HCT AD compared to disease controls. Graft-versus-host disease, viral infection, and donor chimerism had no association with post-HCT AD. Post-HCT AD occurred in 11% at 8 years post-HCT and its occurrence was associated with older age at HCT and unmanipulated graft.
Identifiants
pubmed: 33141919
doi: 10.1007/s10875-020-00895-3
pii: 10.1007/s10875-020-00895-3
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-184Subventions
Organisme : Department of Health
ID : RP-2014-05-007
Pays : United Kingdom
Références
Ahmed I, Teruya J, Murray-Krezan C, Krance R. The incidence of autoimmune hemolytic anemia in pediatric hematopoietic stem cell recipients post-first and post-second hematopoietic stem cell transplant. Pediatr Transplant. 2015;19(4):391–8.
doi: 10.1111/petr.12455
Hwang-Bo S, Kim SK, Lee JW, Jang PS, Chung NG, Jeong DC, et al. Treatment and response of autoimmune cytopenia occurring after allogeneic hematopoietic cell transplantation in children. Blood Res. 2017;52(2):119–24.
doi: 10.5045/br.2017.52.2.119
Kruizinga MD, van Tol MJD, Bekker V, Netelenbos T, Smiers FJ, Bresters D, et al. Risk factors, treatment, and immune dysregulation in autoimmune cytopenia after allogeneic hematopoietic stem cell transplantation in pediatric patients. Biol Blood Marrow Transplant. 2018;24(4):772–8.
doi: 10.1016/j.bbmt.2017.12.782
Chang TY, Jaing TH, Wen YC, Huang IA, Chen SH, Tsay PK. Risk factor analysis of autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in children. Medicine (Baltimore). 2016;95(46):e5396.
doi: 10.1097/MD.0000000000005396
Szanto CL, Langenhorst J, de Koning C, Nierkens S, Bierings M, Huitema ADR, et al. Predictors for autoimmune cytopenias after allogeneic hematopoietic cell transplantation in children. Biol Blood Marrow Transplant. 2020;26(1):114–22.
doi: 10.1016/j.bbmt.2019.07.022
Faraci M, Zecca M, Pillon M, Rovelli A, Menconi MC, Ripaldi M, et al. Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience. Biol Blood Marrow Transplant. 2014;20(2):272–8.
doi: 10.1016/j.bbmt.2013.11.014
Miller PDE, Snowden JA, De Latour RP, Iacobelli S, Eikema DJ, Knol C, et al. Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2020;55(2):441–51.
doi: 10.1038/s41409-019-0680-4
Lum SH, Selvarajah S, Deya-Martinez A, McNaughton P, Sobh A, Waugh S, et al. Outcome of autoimmune cytopenia after hematopoietic cell transplantation for children with primary immunodeficiency. J Allergy Clin Immunol. 2020;146(2):406–16. https://doi.org/10.1016/j.jaci.2020.04.053 .
Holbro A, Abinun M, Daikeler T. Management of autoimmune diseases after haematopoietic stem cell transplantation. Br J Haematol. 2012;157(3):281–90.
doi: 10.1111/j.1365-2141.2012.09070.x
Fischer A, Provot J, Jais JP, Alcais A, Mahlaoui N, members of the CFPIDsg. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. J Allergy Clin Immunol. 2017;140(5):1388–93.e8.
doi: 10.1016/j.jaci.2016.12.978
Lee WY, Oh ES, Min CK, Kim DW, Lee JW, Kang MI, et al. Changes in autoimmune thyroid disease following allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001;28(1):63–6.
doi: 10.1038/sj.bmt.1703102
Isshiki Y, Ono K, Shono K, Onoda M, Yokota A. Autoimmune thyroid dysfunction after allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2016;57(5):1227–9.
doi: 10.3109/10428194.2015.1085532
Au WY, Lie AK, Kung AW, Liang R, Hawkins BR, Kwong YL. Autoimmune thyroid dysfunction after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35(4):383–8.
doi: 10.1038/sj.bmt.1704766
McGrogan A, Seaman HE, Wright JW, de Vries CS. The incidence of autoimmune thyroid disease: a systematic review of the literature. Clin Endocrinol. 2008;69(5):687–96.
doi: 10.1111/j.1365-2265.2008.03338.x
Pasala P, Francis GL. Autoimmune thyroid diseases in children. Expert Rev Endocrinol Metab. 2017;12(2):129–42.
doi: 10.1080/17446651.2017.1300525
Yoshida T, Ueki Y, Suzuki T, Kawagashira Y, Koike H, Kusumoto S, et al. Guillain-Barre syndrome after allogeneic bone marrow transplantation: case report and literature review. eNeurologicalSci. 2016;4:52–5.
doi: 10.1016/j.ensci.2016.08.001
Comert P, Albayrak M, Yildiz A, Sahin O, Ozturk CP, Maral S, et al. An acute transverse myelitis attack after autologous stem cell transplantation: a rare case. Transfus Apher Sci. 2019;58(3):341–3.
doi: 10.1016/j.transci.2019.05.002
Kemp M, Keh YS, Dayanandan R, et al. An atypical cause of longitudinally extensive transverse myelitis after an allogeneic haemopoietic stem cell transplant. J Neurol Neurosurg Psychiatry. 2019;90:e52. https://jnnp.bmj.com/content/90/12/e52.2.citation-tools .
Voss M, Bischof F. Recurrent myelitis after allogeneic stem cell transplantation. Report of two cases. BMC Neurol. 2010;10:76.
doi: 10.1186/1471-2377-10-76
Balls WBLL, Patel RD, Ahmed W, Harshman B, Mori S. Transverse myelitis as a manifestation of graft versus host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(3):S360.
doi: 10.1016/j.bbmt.2016.12.306
Tsutsumi Y, Kamiishi T, Kikuchi R, Ito S, Matsuoka S, Teshima T. Myasthenia gravis after allogeneic bone marrow transplantation: a case report and literature review. Hematol Oncol Stem Cell Ther. 2019;12(2):110–4.
doi: 10.1016/j.hemonc.2017.04.001
Ooi J, Takahashi S, Tajika K, Tojo A, Tani K, Asano S. Immune-mediated optic neuritis after unrelated allogeneic bone marrow transplantation. Blood. 1998;91(7):2619–20.
doi: 10.1182/blood.V91.7.2619
Moesen I, Kidd DP. Bilateral inflammatory optic neuropathy related to graft versus host disease following allogeneic bone marrow transplantation for Hodgkin disease. Neuroophthalmology. 2014;38(4):224–9.
doi: 10.3109/01658107.2014.907321
Tronconi E, Miniaci A, Prete A, Masetti R, Pession A. Juvenile arthritis after haematopoietic stem cell transplantation. Bone Marrow Transplant. 2014;49(9):1244–5.
doi: 10.1038/bmt.2014.110
Bohgaki T, Atsumi T, Koike T. Multiple autoimmune diseases after autologous stem-cell transplantation. N Engl J Med. 2007;357(26):2734–6.
doi: 10.1056/NEJMc076383
Li Z, Rubinstein SM, Thota R, Savani M, Brissot E, Shaw BE, et al. Immune-mediated complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(8):1368–75.
doi: 10.1016/j.bbmt.2016.04.005
Daikeler T, Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol. 2007;20(2):349–60.
doi: 10.1016/j.beha.2006.09.008
Snowden JA, Heaton DC. Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity. Br J Dermatol. 1997;137(1):130–2.
doi: 10.1046/j.1365-2133.1997.17821869.x
Berisso GA, van Lint MT, Bacigalupo A, Marmont AM. Adoptive autoimmune hyperthyroidism following allogeneic stem cell transplantation from an HLA-identical sibling with Graves’ disease. Bone Marrow Transplant. 1999;23(10):1091–2.
doi: 10.1038/sj.bmt.1701760
Bargetzi MJ, Schonenberger A, Tichelli A, Fried R, Cathomas G, Signer E, et al. Celiac disease transmitted by allogeneic non-T cell-depleted bone marrow transplantation. Bone Marrow Transplant. 1997;20(7):607–9.
doi: 10.1038/sj.bmt.1700926
Vialettes B, Maraninchi D. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet. 1993;342(8864):174.
doi: 10.1016/0140-6736(93)91376-W
Smith CI, Aarli JA, Biberfeld P, Bolme P, Christensson B, Gahrton G, et al. Myasthenia gravis after bone-marrow transplantation. Evidence for a donor origin. N Engl J Med. 1983;309(25):1565–8.
doi: 10.1056/NEJM198312223092508
Alajlan A, Alfadley A, Pedersen KT. Transfer of vitiligo after allogeneic bone marrow transplantation. J Am Acad Dermatol. 2002;46(4):606–10.
doi: 10.1067/mjd.2002.117215
Sonwalkar SA, James RM, Ahmad T, Zhang L, Verbeke CS, Barnard DL, et al. Fulminant Crohn’s colitis after allogeneic stem cell transplantation. Gut. 2003;52(10):1518–21.
doi: 10.1136/gut.52.10.1518
Dertschnig S, Hauri-Hohl MM, Vollmer M, Hollander GA, Krenger W. Impaired thymic expression of tissue-restricted antigens licenses the de novo generation of autoreactive CD4+ T cells in acute GVHD. Blood. 2015;125(17):2720–3.
doi: 10.1182/blood-2014-08-597245
Slatter MA, Gennery AR, Cheetham TD, Bhattacharya A, Crooks BN, Flood TJ, et al. Thyroid dysfunction after bone marrow transplantation for primary immunodeficiency without the use of total body irradiation in conditioning. Bone Marrow Transplant. 2004;33(9):949–53.
doi: 10.1038/sj.bmt.1704456